SEC ownership of Marker Therapeutics, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001094038.

Comparable stake leader

Blue Owl Capital Holdings LP

Disclosed value leader

New Enterprise Associates 16, L.P.

Comparable rows

38/50

Latest evidence

31 Mar 2026

Top shareholders Insider holders Latest transactions

Public ticker: MRKR on Nasdaq
Parsed ownership sources: 13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder: Blue Owl Capital Holdings LP
Ranking: Comparable ownership first, then disclosed value
Comparable ownership rows: 38 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder: Blue Owl Capital Holdings LP
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date: 31 Mar 2026
Freshness: Most recent filing date in this holder set
Issuer CIK: 0001094038
Issuer location: Houston, TX

Ownership snapshot

Top shareholders of Marker Therapeutics, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Blue Owl Capital Holdings LP

Disclosed value leader

New Enterprise Associates...

Comparable rows

38/50

Latest evidence

31 Mar 2026

13D/G 13F 3/4/5 Lead comparable stake: 10% 12 rows are not safely comparable across share classes. 13D/G row: Blue Owl Capital Holdings LP Showing 1-8 of 50 holder rows.

Quick read

Blue Owl Capital Holdings LP leads the comparable SEC ownership view at 10%.

38 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Blue Owl Capital Holdings LP's linked filing trail.

Comparable ownership Top 5

Blue Owl Capital Holdings LP 10%

New Enterprise Associates 16, L.P. 9.9%

Alyeska Investment Group, L.P. 9.9%

John R. Wilson 5%

NEA Management Company, LLC 9.6%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Blue Owl Capital Holdings LP	13D/G 13F Company 13D/G 13F	10%	$1,431,356 1,127,052 shares	+$727,459	31 Mar 2025
New Enterprise Associates 16, L.P.	3/4/5 13D/G 10%+ Owner 3/4/5 13D/G	9.9% from 13D/G	$5,202,170 1,625,678 shares	—	23 Dec 2024
Alyeska Investment Group, L.P.	13D/G 13D/G	9.9%	$1,143,378 1,280,952 shares	+$188,600	30 Sep 2025
John R. Wilson	13D/G 3/4/5 John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 · Director 13D/G 3/4/5	5%	— 641,801 shares	$0	19 Aug 2025
NEA Management Company, LLC	13F Company 13F	9.6%	$2,113,381 1,625,678 shares	—	31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC	13F Company 13F	2.3%	$506,115 389,319 shares	—	31 Mar 2026
Aisling Capital Management LP	13F Company 13F	1.9%	$422,981 325,370 shares	—	31 Mar 2026
RENAISSANCE TECHNOLOGIES LLC	13F Company 13F	1%	$227,882 175,294 shares	—	31 Mar 2026

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Aug 2025.

Buys

Insiders: 0

Sells

Insiders: 0

Net

Shares: 0

Window

Last 12 months

4 rolling buckets

Buy value Sell value

Shares: 0 Shares: 0

Window (months)	Buy value	Sell value	Net value
0-3	$0	$0	$0
3-6	$0	$0	$0
6-9	$0	$0	$0
9-12	$0	$0	$0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-18 of 18 reporting-owner rows connected to Marker Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows

Largest Forms 3/4/5 holder

New Enterprise Associates 16, L.P.

Net 12M change

Latest report

17 Nov 2025

Name	Relationship	Holdings Value	Valuation	Report Date
New Enterprise Associates 16, L.P.	10%+ Owner	$5,202,170	Filing P/S	23 Dec 2024
Steve Elms	Director	$1,050,682	Mixed	17 Nov 2025
Peter L. Hoang	President and CEO, Director	$234,297	Mixed	24 Mar 2022
Anthony H. Kim	Chief Financial Officer	$55,479	Mixed	24 Mar 2022
Frederick G. Wasserman	Director	$31,620	Mixed	08 Jun 2021
Anna Szymanska	Vice President, Quality		Mixed	27 Feb 2023
Nadia Agopyan	SVP, Regulatory Affairs		Mixed	27 Feb 2023
Michael Loiacono	Chief Accounting Officer		Mixed	27 Feb 2023
Gerald Garrett	Vice President, Clinical Ops.		Mixed	17 Feb 2022
Mythili Koneru	Chief Medical Officer		Mixed	27 Feb 2023
Katharine Knobil	Director		Mixed	17 Nov 2025
John R. Wilson	Director		Mixed	06 Jun 2023
Eliot M. Lurier	Interim CFO		Mixed	30 Jun 2023
Kathryn Penkus Corzo	Director		Mixed	31 Oct 2025
Tsvetelina P. Hoang	VP, Research and Development		Mixed	27 Feb 2023
Juan Vera	Chief Executive Officer, Director		Mixed	31 Oct 2025
Norman David Eansor	Director		Mixed	17 Nov 2025
David Laskow-Pooley	Director		Mixed	24 May 2022

Recent insider transactions for Marker Therapeutics, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	Shares	Shares owned	Date	Ownership
Katharine Knobil	MRKR	Stock Option (Right to Buy)	Award	221,741	137,330	17 Nov 2025	Direct
Norman David Eansor	MRKR	Stock Option (Right to Buy)	Award	221,741	137,330	17 Nov 2025	Direct
Steve Elms	MRKR	Stock Option (right to buy)	Award	221,741	137,330	17 Nov 2025	Direct
Kathryn Penkus Corzo	MRKR	Stock Option (Right to Buy)	Award	147,611	147,611	31 Oct 2025	Direct
Juan Vera	MRKR	Employee Stock Option (right to buy)	Award	250,000	250,000	31 Oct 2025	Direct

^* marks a reported price that did not pass the local price check.